

WHAT IS CLAIMED IS:

1. A method of modulating migration of a cell within or to the skin of a mammal, said method comprising
 - 5 administering to said mammal an effective amount of:
 - a) an antagonist of MIP-3 α ;
 - b) an agonist of MIP-3 α ;
 - c) an antagonist of CCR6; or
 - d) an agonist of CCR6.
- 10 2. The method of Claim 1, wherein said migration is within said skin.
- 15 3. The method of Claim 2, wherein said migration is chemotactic or chemokinetic.
4. The method of Claim 1, wherein said administering is systemic, local, topical, subcutaneous, intracutaneous, or transdermal.
- 20 5. The method of Claim 1, wherein said cell is a T cell, B cell, dendritic cell, or dendritic cell precursor.
- 25 6. The method of Claim 5, wherein said cell is a T cell.
7. The method of Claim 1, wherein said cell migrates into the dermal and/or epidermal layers of said skin.
- 30 8. The method of Claim 1, wherein said administering is an antagonist of MIP-3 α .
9. The method of Claim 8, wherein said antagonist is selected from:
 - 35 a) a mutein of natural MIP-3 α ;
 - b) an antibody which neutralizes MIP-3 α ; or
 - c) an antibody which binds to CCR6.

10. The method of Claim 8, wherein said mammal is subject to a skin condition, including one selected from cancer, cancer metastasis, autoimmunity, inflammation, 5 infection, psoriasis, skin transplant, or skin graft.
11. The method of Claim 8, wherein said antagonist is administered in combination with an antibiotic, antifungal, antiviral, cancer therapy, or analgesic.
- 10 12. The method of Claim 8, wherein said antagonist is administered in combination with an immune suppressive therapeutic, anti-inflammatory drug, growth factor, or immune adjuvant.
- 15 13. The method of Claim 1, wherein said administering is with a primate MIP-3 α .
14. The method of Claim 13, wherein said modulating 20 is attracting said cell.
15. The method of Claim 14, wherein said cell is attracted to a site of cutaneous lesion.
- 25 16. The method of Claim 13, wherein said primate MIP-3 α is administered in combination with an antibiotic, antifungal, antiviral, or analgesic.
17. The method of Claim 13, wherein said MIP-3 α is 30 administered in combination with a vasodilator, growth factor, cytokine, anti-inflammatory drug, or immune adjuvant.
- 35 18. A method of purifying a population of cells, said method comprising contacting said cells with MIP-3 α , thereby resulting in the identification of cells expressing a receptor for said MIP-3 α .

19. The method of Claim 18, wherein:

- a) said receptor is CCR6; or
- b) said contacting results in specific migration of
5 said cells to a site for purification.

20. The method of Claim 18, wherein said migration is through pores of a membrane.